Opus Genetics, Inc. Earnings Per Share Disclosure
| 11. |
Net loss per share
|
|
2025
|
2024
|
|||||||
|
Warrants
|
22,904,879
|
7,204,299 |
||||||
|
Stock options
|
7,255,635
|
5,073,736
|
||||||
|
RSUs
|
2,091,227
|
1,393,230
|
||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.